Business
Eupraxia Pharmaceuticals Announces Last Patient Last Visit in Phase 2 Osteoarthritis Clinical Trial of EP-104IAR
Eupraxia Pharmaceuticals Announces Last Patient Last Visit in Phase 2 Osteoarthritis Clinical Tri...
About this update from Eupraxia Pharmaceuticals, Inc.
[{"type":"text","content":"\n \n \n \n Eupraxia Pharmaceuticals Announces Last Patient Last Visit in Phase 2 Osteoarthritis Clinical Trial of EP-104IAR\n \n \n /* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n.prntal{\nTEXT-ALIGN: LEFT\n}\n.prntaj{\nTEXT-ALIGN: JUSTIFY\n}\n \n \n \n \n \n \n Canada NewsWire\n \n \n \n \n \n \n VICTORIA, BC\n \n \n ,\n \n \n May 25, 2023\n \n \n /CNW/ - Eupraxia Pharmaceuticals Inc. (\"Eupraxia\" or the \"Company\") (TSX: EPRX), a Phase 2 clinical-stage biotechnology company with an innovative drug delivery technology platform, today announced that it has reached the last patient last visit in its Phase 2 clinical trial of EP-104IAR for osteoarthritis (\"OA\").\n \n \n Dr.\n \n James Helliwell\n \n , CEO of Eupraxia, commented, \"Our team has worked effectively to rapidly advance this study while navigating the unique challenges of a global pandemic. This is an important milestone toward the completion of the study, and we remain on track for top-line data readout in the second quarter of this year.\"\n \n \n Management believes that the top-line data readout will be well powered and has the potential to demonstrate a meaningful reduction in OA knee pain with a corresponding improvement in patient function and an extended duration of effect. Based on previously released blinded safety data the Company also believes EP-104IAR has the potential for a best-in-class safety profile, potentially allowing for bilateral and chronic dosing regimens.\n \n \n The Phase 2 trial readout should also offer important validation of the underlying delivery technology, with highly tunable kinetics and extended duration of effect. The Company intends to further exploit this technology in additional drug candidates.\n \n \n The Phase 2 trial is a randomized, double blind, vehicle-controlled study of 300 OA patients with moderate to severe pain scores as evaluated by Kellgren-Lawrence grade (2-3). The primary endpoint in the study is the difference in change from baseline between EP-104IAR and the vehicle control in (\n \n Western Ontario\n \n and McMaster Universities (\"WOMAC\") pain score at 12...